Hippocampal blood–brain barrier permeability is related to the APOE4 mutation status of elderly individuals without dementia
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Blood–brain barrier (BBB) disruption, modulated by APOE4 mutation, is implicated in the pathogenesis of cognitive decline. We determined whether BBB permeability differed according to cognitive functioning and APOE4 status in elderly subjects without dementia. In this prospective study, 33 subjects with mild cognitive impairment (MCI) and 33 age-matched controls (normal cognition [NC]) underwent 3 T brain magnetic resonance imaging. The Patlak model was used to calculate tissue permeability (K trans). A region-of interest analysis of K trans was performed to compare relevant brain regions. Effects of K trans on cognitive functioning were evaluated with linear regression analysis adjusted for confounding factors. NC and MCI groups did not differ in terms of vascular risk factors or hippocampal K trans, except for hippocampal volume. Hippocampal K trans was significantly higher in APOE4 carriers than in non-carriers ( p = 0.007). Factors which predicted cognitive functioning included hippocampal volume (beta=−0.445, standard error [SE]=0.137, p = 0.003) and hippocampal BBB permeability (beta = 0.142, SE = 0.050, p = 0.008) after correcting for age, education, and APOE4 status. This suggests that hippocampal BBB permeability is associated with APOE4 mutation, and may predict cognitive functioning. BBB permeability imaging represents a distinct imaging biomarker for APOE4 mutations in NC and MCI subjects and for determining the degree of APOE4-related pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“BBB breakdown due to disruption of tight junctions, altered transport of molecules between the blood and the brain, aberrant angiogenesis, vessel regression, brain hypoperfusion, and inflammatory processes may initiate and/or contribute to progressive synaptic and neuronal dysfunction and neurodegenerative disorders.(…”
BackgroundBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · cited 3×
“However, this relationship has been touched upon only very recently in a human study.(32) Our finding is in line with the recent observation of increased BBB permeability in the hippocampus and parahippocampal gyrus in cognitively normal APOE4 carriers, compared to non-carriers.”
MethodResultInfluentialAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 1×
“We aimed to evaluate BBB permeability changes in patients with MCI and normal controls, and hypothesized that increased BBB permeability would follow either the anatomical pattern of common microvascular pathology (white matter) or AD-specific tau pathology (hippocampus, inferior temporal gyrus) or amyloid pathology (…”
MethodInfluentialHalliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
Arvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30029-1 · Cited by 581
Ellis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D., & Heyman, A. (1996) · Neurology · doi:10.1212/wnl.46.6.1592 · Cited by 561
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493 · cited 1×
“Postmortem studies have indicated that APOE4 exacerbates the intraneuronal accumulation of amyloid beta, plaque deposition, formation of neurotoxic amyloid beta oligomers, and severity of cerebral amyloid angiopathy.(35,36) Accumulating evidence suggests that APOE4 mutation influences amyloid pathology via two pathway…”
BackgroundCSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006082 · Cited by 359
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351 · cited 1×
“BBB permeability changes have been extensively investigated in dementia.(5,8,9) Traditionally, the cerebrospinal fluid (CSF)-serum albumin index is used to indicate BBB leakage in human studies.”
BackgroundSando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-9 · Cited by 261 · cited 5×
“The involvement of vascular pathology in AD pathogenesis has become increasingly clear.1 Accumulating evidence shows that vascular involvement in AD pathogenesis is not limited to visible large and/or small vessel pathology but extends to the level of the neurovascular unit or the blood–brain barrier (BBB).2,3 BBB bre…”
BackgroundInfluentialThrippleton, M. J., Backes, W. H., Sourbron, S., Ingrisch, M., van Osch, M. J. P., Dichgans, M., Fazekas, F., Ropele, S., Frayne, R., van Oostenbrugge, R. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.013 · Cited by 252 · cited 9×
“In contrast, dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) uses a gadolinium-based contrast agent of a relatively small molecular weight and is thus more appropriate for measuring the presence and distribution of subtle BBB leakage.(11) Several DCE-imaging studies of AD and mild cognitive impairment…”
BackgroundMethodInfluentialStaging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237
Tracer kinetic modelling for DCE-MRI quantification of subtle blood–brain barrier permeability
Heye, A. K., Thrippleton, M. J., Armitage, P. A., Valdés Hernández, M. D. C., Makin, S. D., Glatz, A., Sakka, E., & Wardlaw, J. M. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2015.10.018 · Cited by 187
Cramer, S. P., & Larsson, H. B. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.126 · Cited by 117
Barnes, S. R., Ng, T. S. C., Montagne, A., Law, M., Zlokovic, B. V., & Jacobs, R. E. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25793 · Cited by 115
APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia
Mirza, S. S., Saeed, U., Knight, J., Ramirez, J., Stuss, D. T., Keith, J., Nestor, S. M., Yu, D., Swardfager, W., Rogaeva, E., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008377 · Cited by 67
Cited by
Choroid Plexus Volume and Permeability at Brain MRI within the Alzheimer Disease Clinical Spectrum
Choi, J. D., Moon, Y., Kim, H.-J., Yim, Y., Lee, S., & Moon, W.-J. (2022) · Radiology · doi:10.1148/radiol.212400 · Cited by 266
Self-citationBlood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
A “multi-omics” analysis of blood–brain barrier and synaptic dysfunction in APOE4 mice
Barisano, G., Kisler, K., Wilkinson, B., Nikolakopoulou, A. M., Sagare, A. P., Wang, Y., Gilliam, W., Huuskonen, M. T., Hung, S.-T., Ichida, J. K., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20221137 · Cited by 78
“Although APOE4 -mediated BBB breakdown has been shown previously in humans (Montagne et al., 2020; Halliday et al., 2016; Moon et al., 2021) and mice (Bell et al., 2012; Nishitsuji et al., 2011; Alata et al., 2015; Cacciottolo et al., 2016), molecular changes of failing BBB have not been studied in…”
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
APOE-Targeted Therapeutics for Alzheimer's Disease
Yassine, H. N., Hugo, C., O'Donovan, B., Stephens, I. O., Johnson, L. A., Cole, G., TCW, J., Johansson, J., Kisler, K., & Chiba-Falek, O. (2025) · The Journal of Neuroscience · doi:10.1523/jneurosci.1388-25.2025 · Cited by 20
Metadata
- Authors
- Moon, W.-J., Lim, C., Ha, I. H., Kim, Y., Moon, Y., Kim, H.-J., & Han, S.-H.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2020-09-16
- Volume
- 41
- Issue
- 6
- Pages
- 1351-1361
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W3087059074
- Cited by
- 66
- References
- 20
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.